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Abstract 
Background: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing 
agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobi-
lization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF.
Methods: Healthy male volunteer donors with a documented average mobilization response to G-CSF received, fol-
lowing ≥6 weeks wash-out, a 1–2 h infusion of 500–2500 µg/kg of balixafortide. Safety, tolerability, pharmacokinetics 
and pharmacodynamics were assessed.
Results: Balixafortide was well tolerated and rated favorably over G-CSF by subjects. At all doses tested balixafor-
tide mobilized HSPC. In the dose range between 1500 and 2500 µg/kg mobilization was similar, reaching 38.2 ± 2.8 
CD34 + cells/µL (mean ± SEM). Balixafortide caused mixed leukocytosis in the mid-20 K/µL range. B-lymphocytosis 
was more pronounced, whereas neutrophilia and monocytosis were markedly less accentuated with balixafortide 
compared to G-CSF. At the 24 h time point, leukocytes had largely normalized.
Conclusions: Balixafortide is safe, well tolerated, and induces efficient mobilization of HSPCs in healthy male vol-
unteers. Based on experience with current apheresis technology, the observed mobilization at doses ≥1500 µg/
kg of balixafortide is predicted to yield in a single apheresis a standard dose of 4× 10E6 CD34+ cells/kg from most 
individuals donating for an approximately weight-matched recipient. Exploration of alternative dosing regimens may 
provide even higher mobilization responses.
Trial Registration European Medicines Agency (EudraCT-Nr. 2011-003316-23) and clinicaltrials.gov (NCT01841476)
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Background
Most autologous and 80% of allogeneic hematopoietic 
stem cell transplantations (HSCT) are currently per-
formed with mobilized peripheral blood stem cells [1]. 
These can be extracted by apheresis from the circulation 
after pretreatment of donors with the cytokine G-CSF, 
currently the most commonly used mobilizing agent [1]. 
Optimal mobilization with G-CSF in donors is relatively 
inconvenient as it takes 4–5  days [2–4]. G-CSF treat-
ment, although generally considered safe, is regularly 
associated with acute (bone pain, flu-like symptoms, 
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suppression of B-lymphopoiesis [10]) adverse events; 
moreover, a considerable list of contra-indications to 
G-CSF has been identified over the years, mostly related 
to the induction of neutrophila and neutrophil activa-
tion, but also to activation of lymphocytes [11]. On the 
recipient side, a greater risk of chronic graft-versus-host 
disease to G-CSF stimulated PBSCT vs. bone marrow-
derived grafts has been reported [12]. Consequently, sig-
nificant activity has been dedicated to the identification 
and development of alternative mobilizing agents that 
would combine predictable, efficient stem cell mobiliza-
tion with single dose activity and good tolerability for 
both donor and recipient.
The ability of CXCR4 antagonists to rapidly dislodge 
stem cells from the marrow has been recognized for 
many years [13]. Previously studied compounds were 
neither universally well tolerated nor very potent [14]. 
The only currently approved CXCR4 antagonist plerixa-
for mobilized a median of 16 CD34+ cells per µL when 
administered alone (without G-CSF) in healthy donors 
[15], which is barely sufficient to generate a normal-sized 
graft in two apheresis sessions.
The synthetic protein epitope mimetic (PEM) peptidic 
CXCR4 antagonist POL5551, a close analogue of the 
clinical stage compound balixafortide (POL6326), shows 
a very wide pharmacodynamic range in preclinical mod-
els and at optimal doses even mobilizes more efficiently 
than G-CSF [16]. In this clinical phase I dose escalation 
trial we evaluated balixafortide with regard to its safety, 
tolerability, pharmacokinetics and mobilization efficiency 
in healthy male volunteers in comparison to G-CSF. 
Balixafortide was well tolerated and rated subjectively 
preferable to G-CSF according to the volunteers. Mobili-
zation was rapid; dose-dependency was apparent at doses 
up to 1500  µg/kg with an average peak mobilization of 
38.2 ± 2.8 CD34 positive cells per µL.
Methods
Volunteers
Volunteers were healthy male HSC donors from the Ger-
man Stem Cell Donor Registry (DSSD) who had received 
a 5-day course of filgrastim (G-CSF, 7.5–10  µg/kg per 
day in 2 divided doses) for matched-unrelated stem 
cell donation and shown a grossly average mobilization 
response (121.6 ± 8.6 CD34+ cells/μL). Additional eligi-
bility (inclusion) criteria for treatment with balixafortide 
were the same as for G-CSF mobilized stem cell dona-
tion [11]. Between G-CSF mobilization/HSPC donation 
and study participation there was a wash-out period of at 
least 6 weeks.
Written informed consent was provided prior to per-
forming any study related activities. The study and 
all related documents were approved by the local 
Institutional Review Board (IRB) (#324/11) and the 
federal medicines agency BfArM (approval #61-3910-
4037635). The trial was registered with the European 
Medicines Agency as EudraCT-Nr. 2011-003316-23 and 
on clinicaltrials.gov as NCT01841476.
Study drug was administered on an in-patient basis in 
the phase I clinical trial unit of Goethe University Medi-
cal Center, the ‘Klinisches Studienzentrum Rhein-Main’. 
Volunteers were discharged 24  h after treatment, to 
return for a follow-up appointment 8–14 days thereafter.
Study design
This was a prospective Phase I open label dose escala-
tion trial; The study design is summarized in Table 1. A 
total of 27 volunteers were treated with balixafortide. A 
treatment consisted of a single intravenous infusion of 
balixafortide in normal saline at doses of 500, 1000, 1500, 
2000 and 2500  μg/kg, based on actual weight, followed 
by sequential clinical and blood analyses (see below). Ini-
tially conceived as a classical 3 + 3 dose escalation design, 
the volunteers were assigned to four groups defined by 
increasing dose levels of balixafortide (500, 1000, 1500, 
and 2000  μg/kg) administered by constant rate infusion 
at over 2  h. Subsequently, amendments were added to 
test additional modalities: Group 6 received 2500  μg/kg 
under the same conditions. Volunteers assigned to Group 
5 received a dose level of 2000 μg/kg by an continuously 
increasing infusion rate (ramp-infusion instead of con-
stant rate infusion) applied over 2 h. In group 7, a dose 
level of 1000  μg/kg was infused over 1  h at a constant 
rate and compared (intra-individually) to the 2 h infusion 
given with an interval of ≥4 weeks. A second balixafor-
tide treatment was furthermore tested in volunteers from 
groups 2, 3 and 6 with groups 2 and 3 receiving 2500 μg/
kg and group 6 given 1500 μg/kg as the second infusion. 
In as far as not all volunteers from the initial phase of the 
study could be recalled, they were replaced by new volun-
teers receiving two treatments, to have a group size of at 
least 3 for each cross-over modality, explaining the varia-
ble dosing group sizes between 3 and 6 (Table 1). Thus, to 
allow for intra-individual comparison, 12 donors received 
a second dose of balixafortide (2 h constant infusion rate 
for all) after a minimum wash-out period of 4 weeks.
Vital signs were monitored immediately prior to and 
in the first 24 h after the start of the infusion of balixa-
fortide; serial blood samples were drawn for biochemical 
safety profiling and pharmacokinetic/pharmacodynamic 
analyses. Given the cationic nature of the compound 
[17] the risk of local or systemic symptoms of histamine 
release was identified and anti-histamine treatment was 
proposed (per protocol) in case of such symptoms. After 
completion of the 2000 µg/kg dosing group the protocol 
was amended to introduce prophylactic anti-histamine 
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treatment in the dosage group ≥2500 µg/kg. Volunteers 
who received prophylactic or therapeutic anti-histamine 
medication are listed accordingly in Table 1.
Objectives
Primary outcome parameters were safety and tolerability 
of balixafortide when compared to G-CSF, pharmacody-
namics of mature and immature blood cell mobilization, 
specifically the intra-individual comparison of balixafor-
tide- and G-CSF-induced mobilization of HSPCs. Sec-
ondary objectives included pharmacokinetic analyses and 
identification of a suitable window for HSPC apheresis.
Pharmacokinetics
Plasma samples were collected at the indicated times and 
kept frozen until immediately before analysis.
Pharmacodynamics
Blood samples were collected at the indicated times 
(Figs.  1, 2, 3, 4, 5 and 6) and kept at room temperature 
(maximum 2–3  h.) until immediately before analysis. 
Complete blood counts were assessed with the Sysmex 
XT1800 hematology analyzer (Norderstedt, Germany). 
CD34+  cells were quantified using the single platform 
flow cytometry analysis with the SCE Kit [Becton–Dick-
inson (BD), Heidelberg, Germany] according to the 
manufacturer’s instructions and ISHAGE guidelines [18]. 
In addition, multi-parametric flow cytometric analyses 
were performed to quantify co-mobilized mature cell 
subsets such as T (CD45+  CD3+), B (CD45+  CD19+) 
and NK (CD45+  CD56+  16+) cells (Multitest, T cells, 
BD), T cell subpopulations (CD45+  CD3+  CD4+/
CD8+, Multitest, TBNL cells, BD) and monocytes 
(CD45+  CD14+, all from BD). In addition, plasmacy-
toid dendritic cell progenitors (pro-pDCs) were identi-
fied as CD45dimCD34dimCD45RA  +  CD123high (all 
moABs from BD). Lyse-no-wash protocols were used in 
conjunction with BD counting beads for direct cell enu-
meration for CD34+ cells and T cell subsets; all other cell 
concentrations were calculated using frequencies rela-
tive to directly enumerated cell species, such as CD34+, 
CD45+ or CD3+ cells.
Circulating colony-forming units-culture (CFU-C) 
were quantified by plating aliquots of lysed peripheral 
blood in commercial cytokine-replete methylcellulose 
media (StemMACS HSC-CFU lite with Epo, human, 
Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany).
Statistical analysis
Unless otherwise mentioned, data are expressed as 
mean ±  SEM. Descriptive statistics and Student’s t-test 
for paired or unpaired analysis (as appropriate) were cal-
culated using Excel. A p < 0.05, Bonferroni-corrected for 




A summary of adverse events that were documented 
throughout the trial is shown in Table  2. No severe 
adverse events (SAEs) were observed. Mild skin reactions 
Table 1 Study design
A total of 27 volunteers were treated with 39 doses of balixafortide
In italics volunteers with histamine release associated AE
H Anti-histamine premedication










 Volunteer 1 500/2/constant _
 Volunteer 2 500/2/constant
 Volunteer 3 500/2/constant
Group 2
 Volunteer 1 1000/2/constant 2500/2/constantH
 Volunteer 2 1000/2/constant 2500/2/constantH
 Volunteer 3 1000/2/constant –
 Volunteer 4 1000/2/constant 2500/2/constantH
Group 3
 Volunteer 1 1000/1/constanth 1000/2/const. rate
 Volunteer 2 1000/1/constant 1000/2/const. rate
 Volunteer-3 1000/1/constant 1000/2/const. rate
Group 4
 Volunteer 1 1500/2/constant 2500/2/const. rateH
 Volunteer 2 1500/2/constanth 2500/2/const. rateH
 Volunteer 3 1500/2/constant –
 Volunteer 4 1500/2/constant 2500/2/const. rateH
Group 5
 Volunteer 1 2000/2/constanth –
 Volunteer 2 2000/2/constant
 Volunteer 3 2000/2/constanth
 Volunteer 4 2000/2/constanth
 Volunteer 5 2000/2/constanth
 Volunteer 6 2000/2/constanth
Group 6
 Volunteer 1 2000/2/ramped –
 Volunteer 2 2000/2/rampedh
 Volunteer 3 2000/2/ramped
Group 7
 Volunteer 1 2500/2/constantH –
 Volunteer 2 2500/2/constantH 1500/2/const. rate
 Volunteer 3 2500/2/constantH 1500/2/const. rate
 Volunteer 4 2500/2/constantH 1500/2/const. rate
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such as flushing, urticaria or local itching were reported 
by 1/3, 4/10, 2/7, 8/9 and 7/10 volunteers receiving 500, 
1000, 1500, 2000 and 2500 µg/kg of balixafortide respec-
tively. Upon treatment with a combination of H1 and H2 
blockers symptoms rapidly abated. These reactions were 
rated likely related to study drug.
Three adverse events (AEs) were considered possibly 
related to study drug: mild bone pain (1 subject), an unex-
plained elevation in serum creatinine kinase (2 subjects), 
and a systolic blood pressure reading of >150 mmHg (2 
subjects).
Constant-slope infusion, tested at the 2000 µg/kg dose 
level in three volunteers (group 6), as well as increased 
infusion rates (1 vs. 2 h, group 3), tested in paired analy-
ses in three volunteers at the 1000 µg/kg dose level, did 
not influence the tolerability of the agent (Table 1).
At the time of follow-up, volunteers were questioned 
about their subjective rating of G-CSF vs. balixafortide as 
mobilizing agents; there was an overwhelming preference 
for balixafortide. See also Table  3 for the questionnaire 
and volunteer responses.
Pharmacokinetics
Serial plasma samples were assayed for balixafortide con-
centrations and pharmacokinetic parameters were calcu-
lated using Phoenix WinNonlin 6.4. We observed dose 
linearity for both Cmax and AUC (Fig. 1a). The volume of 
distribution was approximately 500–600  mL/kg. Balixa-
fortide was cleared from plasma with a terminal half-life 
of approximately 5  h over all application schemes and 
doses of 5:45 ± 0:35 h (mean ± SD; Fig. 1b). The clear-
ance of balixafortide appeared to be almost equal to the 
a b
c d
Fig. 1 Pharmacokinetics. a Cmax (left Y-axis) and AUC (right Y-axis) are plotted as a function of dose (X-axis). Dose-linear pharmacokinetics were 
observed. n = 3–6. b Dose-dependent pharmacokinetic profiles are shown. Cmax was reached at the end of infusion and balixafortide was cleared 
quickly from the circulation thereafter. n = 3–6. c Comparative pharmacokinetics of balixafortide (1000 µg/kg) infused over 1 vs. 2 h. Cmax was 
higher and reached earlier for 1-h dosing, but AUC was similar (data not shown). n = 3. d Comparative pharmacokinetics of linear vs. ramped 
infusion rate at the 2000 µg/kg dose level. Cmax was notably higher but AUC was virtually identical for both infusion types. n = 3. Mean ± SEM are 
shown throughout
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glomerular filtration rate suggesting that balixafortide 
is mainly cleared through the kidney. Different infusion 
durations (1 vs. 2  h) did not notably influence the PK 
profile except for an earlier Cmax (Fig. 1c), and the same 
applied to ‘constant-slope’ vs. ‘ramp’ infusion (Fig. 1d).
Pharmacodynamics—mobilization of immature cells
At all doses tested, balixafortide infusions quickly resulted 
in an increase in circulating HSPCs, as measured phe-
notypically (CD34+  cells, Fig.  2a) or functionally in col-
ony assays (Fig.  2b). Clonogenicity of balixafortide vs. 
G-CSF mobilized CD34+  cells was lower with 1  CFU-C 
out of 5.9 ±  0.5 balixafortide mobilized CD34+  cells vs. 
1  CFU-C out of 3.2  ±  0.2 CD34+  cells mobilized with 
G-CSF (Fig. 2c). At lower doses (500 vs. 1000 vs. 1500 µg/
kg), dose-dependent mobilization was clearly observed, 
while the later dose increments to 2000 and 2500  µg/kg 
did not result in a commensurate increase in the number 
of mobilized HSPC compared to 1500  µg/kg (Fig.  3a, b). 
This was confirmed in paired analyses in small cohorts 
(Fig.  3c). Therefore, for some analyses all mobilization 
data for doses  ≥1500  µg/kg are analyzed together. As 
such, mean peak mobilization in response to doses of 
1500–2500 µg/kg was 38.2 ± 2.8 CD34+ cells/µL (Fig. 3d). 
Thus at these doses intra-individual comparison of balixa-
fortide vs. G-CSF induced mobilization revealed that—on 
a b
c
Fig. 2 Pharmacodynamics: mobilization of immature hematopoietic cells. a, b Dose-dependent mobilization of phenotypically (CD34+ , panel a) 
or functionally (CFU-C, panel b) defined stem and progenitor cells (HSPCs). HSPC mobilization was observed at all dose levels. Mobilization at the 
lowest dose level peaked 1 h after the end of the infusion and was delayed after higher doses. Dose dependence was observed for the first three 
dosing steps (n = 3–6, mean ± SEM). c The ratio between circulating CD34+ cells and CFU-C is shown for all doses. Clonogenicity of balixafortide 
mobilized CD34+ tended to be lower than for G-CSF mobilized CD34+ cells. Symbols represent individual values, the short horizontal bar and whisk-
ers mean ± SEM. n = 3–6
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average—the G-CSF regimen was about three times as 
effective as the CXCR4 antagonist. There appeared to be 
a good correlation between the two mobilizing agents 
(Fig. 3d), suggesting that—as had been shown in mice [16, 
19]—good mobilizers mobilize efficiently with either agent 
and poor mobilizers are refractory to both.
Peak mobilization at the 500 µg/kg dose was observed 
1 h after the end of the balixafortide infusion/after reach-
ing Cmax (Figs.  1b, 2a). At higher doses, the observed 
mobilization peak appeared later, approximately 4  h 
after the end of the infusion. Thereafter, the number of 
circulating CD34+  cells slowly decreased but remained 
elevated beyond baseline at the 24 h time point for all 
except the lowest dose (Fig. 2a, b). Constant-slope (ramp) 
vs. constant-rate infusions (at 2000  µg/kg only) had no 
discernible effect on stem cell mobilization efficiency, 
and the same applied to infusion rate (1 vs. 2 h) (Fig. 4).
A population of “stem cells” co-expressing CD45RA 
and CD123, previously described in blood of plerixafor-
mobilized donors and identified as plasmacytoid den-
dritic cell progenitors (pro-pDCs) [20], was detected at 
high frequencies (22.4  ±  2.3% of SSCdim/FSCmid-hi/
CD45dim/CD34+  cells) after balixafortide-treatment, 
but was rare after G-CSF (Fig. 5).
a b
c d
Fig. 3 Mobilization of immature hematopoietic cells: comparison with G-CSF. Baseline circulating CD34+ cells, balixafortide mobilized CD34+ cells 
(incremental balixafortide dose as indicated on X-axis) and G-CSF mobilized CD34+ cells (same G-CSF dose for all groups, see “Methods” section) 
are displayed in (a). Corresponding fold-increase data are shown in (b). Symbols represent individual values, the short horizontal bar and whiskers 
mean ± SEM. n = 3–6. c Intra-individual comparison of peak mobilization with 1000 vs. 2500 µg/kg (left panel, n = 3) or 1500 vs. 2500 µg/kg (right 
panel, n = 6) of balixafortide is shown. 2500 µg/kg balixafortide mobilized more CD34+ cells than 1000 µg/kg, whereas no difference between 
peak mobilization with 1500 vs. 2500 µg/kg was observed. Symbols represent individual values. d The good correlation between effectiveness of 
G-CSF vs. balixafortide with respect to CD34+ cell mobilization is displayed for balixafortide doses between 1500 and 2500 µg/kg n = 14. Symbols 
represent individual values (constant rate only)
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Pharmacodynamics—mobilization of mature 
hematopoietic cells
Stem cell mobilization was accompanied with mixed 
leukocytosis affecting all cell lineages. It followed the 
same kinetics as stem cell mobilization and was dose-
dependent as well as short-lived. At balixafortide doses 
of 1500–2500  µg/kg white blood counts (WBCs) of 
25.3 ± 1.4 × 10*3 WBC/µL were reached, i.e. balixafor-
tide mobilized approximately half as many mature cells 
as G-CSF (Fig.  6a). The lineage distribution of mature 
leukocytes differed markedly between both agents, in 
that balixafortide mobilized higher relative and absolute 
numbers of B-cells and fewer myeloid cells (Fig.  6b, c). 
The ratio between T-lymphocytes and CD34+  cells was 
26.2 ± 1.98:1 in G-CSF mobilized blood, vs. 95.7 ± 8.9:1 
in balixafortide mobilized blood, predicting that apher-
esis products from balixafortide mobilized donors will 
contain more T-cells than from G-CSF treated donors. 
Within the T cell population the proportion of T helper 
(CD4+) and cytotoxic T cells (CD8+) was very similar 
between the differently mobilized blood specimens as 
well as compared to steady state (baseline) (Fig. 6d).
Discussion
We performed a Phase I clinical trial to directly compare 
the novel CXCR4 antagonist balixafortide with the stand-
ard mobilizing agent G-CSF, with regard to the follow-
ing parameters: safety and tolerability, pharmacokinetic 
profile, and pharmacodynamic effects; the latter were 
defined as mobilization volumes of immature and mature 
a b
c d
Fig. 4 Mobilization of immature hematopoietic cells: effects of infusion velocity and rate. a, b Inter-individual comparison of CD34+ cell mobiliza-
tion after infusion of balixafortide over 1 vs. 2 h demonstrates equivalent mobilization kinetics (a) and peak mobilization responses (b). This cohort 
received only a single course of G-CSF, hence the data shown for G-CSF mobilization with each of the baselines and balixafortide treatments are 
the same. Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3. c, d Comparison of CD34+ cell mobiliza-
tion after ramped vs. constant rate infusion of balixafortide demonstrates equivalent mobilization kinetics (c) and peak mobilization responses (d). 
Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3
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blood cells. At the doses tested, balixafortide was asso-
ciated with few adverse effects, and none of these were 
dose limiting. Skin symptoms compatible with possible 
local histamine release syndrome were observed with 
some regularity but could easily be managed with routine 
co-administration of anti-histamines.
Mechanistically, mobilization with CXCR4 antagonists 
like balixafortide involves a rather short-lived interfer-
ence with stem cell retention in the bone marrow [13]. 
Therefore some of the proposed (albeit never robustly 
substantiated) long-term adverse effects of G-CSF should 
not rationally be associated with balixafortide treatment. 
Specifically, we speculate that, unlike G-CSF, balixa-
fortide may be a safe mobilizing agent for patients (and 
donors) with autoimmune conditions [21, 22] as well as 
sickle cell disease [23, 24]. Formal questionnaires also 
confirm good tolerability and, in fact, indicate a prefer-
ence for balixafortide vs. GCSF, although the study set-
ting may have favored balixafortide.
The higher balixafortide doses tested in this study 
mobilized 38.2  ±  2.8 CD34+  cells/µL. In view of the 
currently available technologies [25, 26] this is suffi-
cient to generate a stem cell product with an average of 
5× 10E6 CD34 + donor cells/kg as per a single apheresis; 
this constitutes an adequate number of cells for the aver-
age PBSCT [i.e.  >4×  10E6/kg (weight of recipient), and 
would even accommodate patients with a body weight 
that is somewhat higher than their donor. That said, data 
in mice [16] and cynomolgus monkeys (unpublished) 
indicated a semi-logarithmic dose-response relationship 
with a high ceiling; extrapolating from these data we pos-
tulate that further dose increments of balixafortide are 
possible. Further studies with higher doses of balixafor-
tide are therefore warranted as meaningfully higher stem 
cell yields may be achieved—provided these doses are 
well tolerated.
The comparator agent in our study was G-CSF given 
in split doses as is routine practice in our center [7]; 
the rationale is twofold: more efficient mobilization and 
potentially better tolerability [27–30]. The alternative 
regimen that is widely used in the USA employs the same 
daily dose but makes use of a single injection for which 
Fig. 5 Mobilization of plasmacytoid dendritic cell (pDC) progenitors. Displayed are representative flow cytograms of putative pro-pDCs (defined as 
CD34dimCD45dimCD45RA+CD123high) detected in G-CSF (top) or balixafortide (bottom) mobilized blood. Mean (±SEM) percentages of pDC progeni-
tors within the HSPC fraction CD34+CD45dim detected in all G-CSF and balixafortide (1st treatment, constant infusion rate, 2 h, Table 1) mobilized 
specimen (n = 21) are shown in the bottom
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average CD34+ cell counts in the mid-sixties’ range (per 
µL) were reported [6] i.e. less than two-thirds of what is 
achieved with split-dose G-CSF. Thus the advantage in 
efficiency of single-dose G-CSF vs. balixafortide at the 
doses tested here would be less than twofold.
High frequencies of a population presumed to rep-
resent precursors of plasmacytoid dendritic cells (pro-
pDCs) were previously detected in plerixafor-mobilized 
blood [20] and were also found by us in balixafortide-
mobilized blood (Fig.  5). This indicates a substance 
class specific mobilization effect and is in fact in line 
with reports showing the importance of the CXCR4/
CXCL12 pathway in pro-pDC development (and reten-
tion) in mice [31]. The biological function of pro-pDCs 
in a graft is unclear. As they have been associated with 
immunomodulatory functions [32] such as promotion of 
regulatory T cell differentiation [33, 34], it is tempting to 
speculate about a possible role in modulating graft-ver-
sus-host disease (GvHD). Indeed, in a cohort of patients 
receiving a plerixafor-mobilized graft only 1/20 devel-
oped acute GvHD 3° or 4° [15] which is markedly less 
than would be expected with G-CSF-mobilized blood 
[12, 35, 36] and which was not accompanied by an exces-
sive relapse rate. These data are potentially meaningful 
given the much higher T-cell dose co-transplanted with a 
CXCR4 antagonist-mobilized graft.
As all other mobilizing regimes, mobilization by 
balixafortide was associated with marked leukocytosis; 
the-fold difference for mature and immature cell mobi-
lization between G-CSF and balixafortide was quite 
a b
c d
Fig. 6 Pharmacodynamics: mobilization of mature hematopoietic cells. a Balixafortide induces dose-dependent leukocytosis with the same kinet-
ics as observed for CD34+ cells (n = 3–6, mean ± SEM); -fold difference between mature cell mobilization with balixafortide and G-CSF was equiva-
lent to that for CD34+ cells. Differential mobilization of leukocyte subsets was observed, with lower monocyte (b), higher B-cell (c), but similar T-cell 
(total, CD4+ and CD8+ T-cells, d mobilization after balixafortide vs. G-CSF induced mobilization (n = 3–6, mean ± SEM). G-CSF was administered at 
the same dose in all groups; the symbol used links mobilization results to a certain balixafortide dosing group
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similar. However, the distribution of leukocyte subtypes 
was markedly different; specifically the virtually diag-
nostic left-shifted neutrophilia in G-CSF treated volun-
teers [2, 5] was not observed after balixafortide. These 
observations support the prediction that balixafortide 
mobilizes without stimulation and lineage skewing and 
might thus be suitable for patients in whom such could 
result in undesirable side effects.
One of the desired features of a mobilizing agent is pre-
dictability of efficacy. Mouse data clearly indicate that 
mobilization efficiency is dominated by genetics [37, 38] 
but that the delta or-fold difference (e.g. between C57Bl/6 
and DBA/2 mice) is much closer for CXCR4 antagonists 
than for G-CSF [16]. Although differences in G-CSF 
mobilization efficiency in our trial were less apparent 
due to inclusion criteria (average mobilization), our data 
clearly confirm the strong donor-inherent component 
for the efficiency of stem cell mobilization per se on the 
one hand and less pronounced variability in mobilization 
response with balixafortide on the other hand.
Conclusion
We have demonstrated that HSPC mobilization with 
balixafortide can be both efficient and predictable; more 
potent mobilization may be achievable with higher doses 
of this agent, as future studies may be able to show. Balix-
afortide treatment was safe and well tolerated. Because 
of its mechanism of action along with its rapid elimina-
tion, this stem cell mobilizing agent can be considered 
an option for many of the patients and donors with 
contra-indications to G-CSF. Its brisk mobilization after 
Table 2 Safety and tolerability of balixafortide. Summary of adverse events
A total of 27 volunteers were treated with 39 doses of balixafortide. Therefore some volunteers (12) were included in two different groups, when adverse events per 
dose-group were assessed. Responses to all items were binary (yes/no), not quantitative; multiple responses were possible
Dose (μg/kg) 500 1000 1000 1500 2000 2000 2500
Infusion time/rate 2 h./const. 2 h./const. 1 h./const. 2 h./const. 2 h./const. 2 h./ramp 2 h./const.
n Volunteers 3 7 3 7 6 3 10
Volunteers with AE 1 5 1 2 6 2 7
Erythema 1 4 7
Pruritus 2 1 1 4 2
Infusion site erythema 1 2





Blood CK increased 2








Table 3 Safety and tolerability of balixafortide. Subjective 
rating
Side effects in the course of treatment with: G-CSF Balixafortide
Abdominal pain 2 0
Bone pain 24 0
Headache 11 1
Skin reactions 1 13








 Easy to use 7 29
 Acceptable 13 30
 More convenient overall 2 32
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one single dose is also highly convenient for donors and 
apheresis centers. In aggregate, balixafortide could be 
developed as an alternative single-agent mobilizing agent 
for patients and donors alike. By extension, our work 
also demonstrates the potential of PEM technology for 
rational drug design.
Authors’ contributions
DK, SB, EW, AK, BS performed research. DK, JG, HM, AW, CE, GD, BR, EC, KD, LH 
and HB planned and analysed experiments. DK and HB wrote the paper. CE 
and LH edited the manuscript. HB bears the overall responsibility for the stud-
ies. All authors discussed, commented on and approved the final version of 
the manuscript. All authors read and approved the final manuscript.
Author details
1 German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, 
Germany. 2 Clinical Trial Center Rhein-Main (KSRM), Pharmazentrum Frankfurt/
ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt, 
Germany. 3 Department of Medicine II, Goethe University, Frankfurt, Germany. 
4 Polyphor Ltd, Allschwil, Switzerland. 5 Institute for Transfusion Medicine 
and Immunohematology, Goethe University, Sandhofstr. 1, 60528 Frankfurt, 
Germany. 6 Department of Medicine, Division of Hematology, University 
of Washington, Seattle, WA, USA. 7 Present Address: Department of Internal 
Medicine, Division of Oncology, Section of Stem Cell Biology, Washington 
University Medical School, St. Louis, MO, USA. 
Acknowledgements
DK is a scholar of the German Academic Exchange Service (Postdoctoral 
fellowship-ID: 57054578, 2014-2016). HB is a member of LOEWE Cell and Gene 
Therapy Frankfurt faculty, funded by Hessian Ministry of Higher Education, 
Research and the Arts ref.no.: III L 4- 518/17.004 (2013). HB acknowledges 
funding by Deutsche Forschungsgemeinschaft grant BO3553/1-1.
Competing interests
The study was sponsored and largely funded by Polyphor, makers and suppli-
ers of the compound tested here, and several co-authors were or are employ-
ees of Polyphor (AW, CE, GD, BR, EC, KD, LH). HB has received research funding 
from Polyphor (makers of balixafortide), has received research funding and has 
served on the advisory board and speakers’ bureau of Sandoz-Hexal (makers 
of a biosimilar Filgrastim G-CSF), has received research funding from Chugai 
(makers of Lenograstim G-CSF) and has received honoraria from Genzyme 
(makers of plerixafor).
Availability of data and materials
The datasets analysed during the current study available from the correspond-
ing author and with permission of Polyphor Inc. on reasonable request.
Ethics approval and consent to participate
The study and all related documents were approved by the local Institu-
tional Review Board (IRB) (#324/11) and the federal medicines agency BfArM 
(approval #61-3910-4037635). The trial was registered with the European 
Medicines Agency as EudraCT-Nr. 2011-003316-23 and on clinicaltrials.gov as 
NCT01841476.
Funding
The study was sponsored and largely funded by Polyphor, makers and suppli-
ers of the compound tested here.
Received: 10 October 2016   Accepted: 8 December 2016
References
 1. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz 
M, et al. Quantitative and qualitative differences in use and trends of 
hematopoietic stem cell transplantation: a global observational study. 
Haematologica. 2013;98:1282–90.
 2. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte 
colony-stimulating factor in healthy individuals: recent findings and cur-
rent challenges. Blood. 2008;111:1767–72.
 3. Kroger N, Kruger W, Renges H, Zeller W, Rauhoft C, Loliger C, et al. Com-
parison of progenitor cell collection on day 4 or day 5 after steady-state 
stimulation with G-CSF alone in breast cancer patients: influence on 
CD34+ cell yield, subpopulation, and breast cancer cell contamination. J 
Hematother Stem Cell Res. 2000;9:111–7.
 4. Kroger N, Zander AR. Dose and schedule effect of G-GSF for stem cell 
mobilization in healthy donors for allogeneic transplantation. Leuk Lym-
phoma. 2002;43:1391–4.
 5. Anderlini P. Effects and safety of granulocyte colony-stimulating factor in 
healthy volunteers. Curr Opin Hematol. 2009;16:35–40.
 6. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt 
AH, et al. Safety and efficacy of hematopoietic stem cell collection from 
mobilized peripheral blood in unrelated volunteers: 12 years of single-
center experience in 3928 donors. Blood. 2009;114:3757–63.
 7. Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C, et al. 
Safety and efficacy of healthy volunteer stem cell mobilization with fil-
grastim G-CSF and mobilized stem cell apheresis: results of a prospective 
longitudinal 5-year follow-up study. Vox Sang. 2013;104:46–54.
 8. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, 
et al. Adverse events among 2408 unrelated donors of peripheral blood 
stem cells: results of a prospective trial from the National Marrow Donor 
Program. Blood. 2009;113:3604–11.
 9. Winkler IG, Pettit AR, Raggatt LJ, Jacobsen RN, Forristal CE, Barbier V, et al. 
Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide 
or AMD3100 have distinct mechanisms of action on bone marrow HSC 
niches and bone formation. Leukemia. 2012;26:1594–601.
 10. Winkler IG, Bendall LJ, Forristal CE, Helwani F, Nowlan B, Barbier V, et al. 
B-lymphopoiesis is stopped by mobilizing doses of G-CSF and is rescued 
by overexpression of the anti-apoptotic protein Bcl2. Haematologica. 
2013;98:325–33.
 11. Brauninger S, Thorausch K, Luxembourg B, Schulz M, Chow KU, Seifried 
E, et al. Deferrals of volunteer stem cell donors referred for evaluation 
for matched-unrelated stem cell donation. Bone Marrow Transplant. 
2014;49:1419–25.
 12. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. 
Peripheral-blood stem cells versus bone marrow from unrelated donors. 
N Engl J Med. 2012;367:1487–96.
 13. Karpova D, Bonig H. Concise review: CXCR4/CXCL12 signaling in imma-
ture hematopoiesis—lessons from pharmacological and genetic models. 
Stem Cells. 2015;33:2391–9.
 14. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem 
and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 
2012;26(1):34–53.
 15. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid 
mobilization of functional donor hematopoietic cells without G-CSF 
using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 
2008;112:990–8.
 16. Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, et al. 
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem 
and progenitor cells with greater efficiency than Plerixafor. Leukemia. 
2013;27:2322–31.
 17. DeMarco SJ, Henze H, Lederer A, Moehle K, Mukherjee R, Romagnoli 
B, et al. Discovery of novel, highly potent and selective beta-hairpin 
mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharma-
cokinetic profiles. Bioorg Med Chem. 2006;14:8396–404.
 18. Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, Tonn T. Enumeration 
of viable CD34(+) cells by flow cytometry in blood, bone marrow and 
cord blood: results of a study of the novel BD stem cell enumeration kit. 
Cytotherapy. 2011;13:449–58.
 19. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, 
et al. Rapid mobilization of murine and human hematopoietic stem 
and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 
2005;201:1307–18.
 20. Cashen A, Rettig MP, Gao F, Abboud CN, Stockerl-Goldstein KE, Voj R, Uy 
GL, Westervelt P, DiPersio JF. Phase I Study of intravenous plerixafor added 
to a mobilization regimen of G-CSF in lymphoma patients undergoing 
autologous stem cell collection. ASH Annual Meeting and Exposition. 
2010.
Page 12 of 12Karpova et al. J Transl Med  (2017) 15:2 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 21. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, 
et al. Granulocyte colony-stimulating factor administration to healthy 
volunteers: analysis of the immediate activating effects on circulating 
neutrophils. Blood. 1994;84:3885–94.
 22. Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, et al. 
G-CSF as immune regulator in T cells expressing the G-CSF receptor: 
implications for transplantation and autoimmune diseases. Blood. 
2003;102:734–9.
 23. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. 
Lancet. 1998;351:959.
 24. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte 
colony-stimulating factor (G-CSF) administration in individuals with sickle 
cell disease: time for a moratorium? Cytotherapy. 2009;11:464–71.
 25. Hequet O. Hematopoietic stem and progenitor cell harvesting: technical 
advances and clinical utility. J Blood Med. 2015;6:55–67.
 26. Reinhardt P, Brauninger S, Bialleck H, Thorausch K, Smith R, Schrezenmeier 
H, et al. Automatic interface-controlled apheresis collection of stem/
progenitor cells: results from an autologous donor validation trial of a 
novel stem cell apheresis device. Transfusion. 2011;51:1321–30.
 27. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, et al. A 
randomized comparison of once versus twice daily recombinant human 
granulocyte colony-stimulating factor (filgrastim) for stem cell mobiliza-
tion in healthy donors for allogeneic transplantation. Br J Haematol. 
2000;111:761–5.
 28. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander 
AR. Kinetics of G-CSF and CD34 + cell mobilization after once or twice 
daily stimulation with rHu granulocyte-stimulating factor (lenograstim) 
in healthy volunteers: an intraindividual crossover study. Transfusion. 
2004;44:104–10.
 29. Kroger N, Zeller W, Hassan HT, Kruger W, Gutensohn K, Loliger C, et al. 
Stem cell mobilization with G-CSF alone in breast cancer patients: 
higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) 
compared to a single dose (1 × 10 microg/kg). Bone Marrow Transplant. 
1999;23:125–9.
 30. Lee V, Li CK, Shing MM, Chik KW, Li K, Tsang KS, et al. Single vs twice daily 
G-CSF dose for peripheral blood stem cells harvest in normal donors 
and children with non-malignant diseases. Bone Marrow Transplant. 
2000;25:931–5.
 31. Kohara H, Omatsu Y, Sugiyama T, Noda M, Fujii N, Nagasawa T. Develop-
ment of plasmacytoid dendritic cells in bone marrow stromal cell niches 
requires CXCL12-CXCR4 chemokine signaling. Blood. 2007;110:4153–60.
 32. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid den-
dritic cells: recent progress and open questions. Annu Rev Immunol. 
2011;29:163–83.
 33. Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the 
induction of T-regulatory cells. Hum Immunol. 2002;63:1149–55.
 34. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid 
dendritic cells prime IL-10-producing T regulatory cells by inducible 
costimulator ligand. J Exp Med. 2007;204:105–15.
 35. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, et al. 
Long-term outcomes after transplantation of HLA-identical related 
G-CSF-mobilized peripheral blood mononuclear cells versus bone mar-
row. Blood. 2012;119:2675–8.
 36. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone mar-
row. Curr Opin Oncol. 2012;24:191–6.
 37. Roberts AW, Foote S, Alexander WS, Scott C, Robb L, Metcalf D. 
Genetic influences determining progenitor cell mobilization and 
leukocytosis induced by granulocyte colony-stimulating factor. Blood. 
1997;89:2736–44.
 38. Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, et al. 
Pharmacological inhibition of EGFR signaling enhances G-CSF-induced 
hematopoietic stem cell mobilization. Nat Med. 2010;16:1141–6.
